Sales of Biogen Idec's Tysabri curbed by PML cases
This article was originally published in Scrip
Biogen Idechas reduced its sales growth projections for its multiple sclerosis drug Tysabri (natalizumab), following another case of progressive multifocal leucoencephalopathy (PML) in a patient who had been receiving the drug – the fifth case reported in the past 12 months.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.